Liberyx Therapeutics
Biotechnology Research • 
China • 1-10 Employees
Company overview
| Headquarters | China |
| Website | |
| Keywords | Biopharma, UCD, Neurometabolic Disorders, NKH, Rare Pediatric |
| Founded | 2021 |
| Employees | 1-10 |
Key Contact at Liberyx Therapeutics
Gershon Koh
Board Director
About Liberyx Therapeutics
Liberyx Therapeutics is an innovative clinical-stage biopharma combating rare pediatric neurometabolic disorders. We are focused on developing safe, patient-friendly treatments for neurometabolic disorders such as nonketotic hyperglycinemia (NKH) and urea cycle disorders (UCD).
$
Liberyx Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Funding Data
Liberyx Therapeutics has never raised funding before.
United Kingdom
Spain
Australia
United States
Frequently asked questions
Liberyx Therapeutics is located in CN.
Liberyx Therapeutics was founded in 2021, making it 5 years old. The company has established itself as a significant player in its industry over this time.
Liberyx Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
